Table 4 Drug-drug interactions and predicted plasma levels of oral anticoagulants and targeted cancer therapies
From: Management of atrial fibrillation in patients taking targeted cancer therapies
| Oral Anticoagulants | ||||||
|---|---|---|---|---|---|---|
| Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | ||
|
Tyrosine Kinase Inhibitors | Afatinib | |||||
| Axitinib | ||||||
| Bosutinib | ||||||
| Cabozantinib | ||||||
| Ceritinib | ↑OAC levels | ↑OAC levels | ↑OAC levels | |||
| Crizotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
| Dasatinib | ↑OAC levels & effect | ↑OAC effect | ↑OAC levels & effect | ↑OAC levels & effect | ↑OAC effect | |
| Erlotinib | ↑OAC levels | |||||
| Gefitinib | ↑OAC effect | |||||
| Ibrutinib | ↑OAC effect | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | |
| Imatinib | ↑OAC levels & effect | ↑OAC levels | ↑OAC levels | |||
| Lapatinib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ||
| Lenvatinib | ||||||
| Nilotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
| Osimertinib | ↑OAC levels | ↑OAC levels | ↑OAC levels | |||
| Pazopanib | ||||||
| Ponatinib | ||||||
| Regorafenib | ↑OAC effect | |||||
| Ruxolitinib | ||||||
| Sorafenib | ↑OAC levels & effect | ↑OAC levels | ||||
| Sunitinib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ||
| Vandetanib | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ||
- Drug-drug interactions are predicted based on pharmacokinetics, given the limited data available from patient studies
- Underlined = "Alter combination"
-
